Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.22
+8.4%
$9.60
$2.24
▼
$12.54
$1.42B2.224.33 million shs2.25 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$139.69
-2.6%
$145.93
$93.90
▼
$156.92
$344.03B0.1310.49 million shs2.70 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$2.87
+5.3%
$3.75
$2.50
▼
$5.24
$1.78B1.1519.70 million shs11.65 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
+1.47%-23.97%-8.12%-24.12%+165.03%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.02%-3.37%-2.05%-6.04%+53.87%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-6.21%-23.38%-21.39%-22.29%-33.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.22
+8.4%
$9.60
$2.24
▼
$12.54
$1.42B2.224.33 million shs2.25 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$139.69
-2.6%
$145.93
$93.90
▼
$156.92
$344.03B0.1310.49 million shs2.70 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$2.87
+5.3%
$3.75
$2.50
▼
$5.24
$1.78B1.1519.70 million shs11.65 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
+1.47%-23.97%-8.12%-24.12%+165.03%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.02%-3.37%-2.05%-6.04%+53.87%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-6.21%-23.38%-21.39%-22.29%-33.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.83
Moderate Buy$14.9081.38% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$155.7411.49% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$7.52162.48% Upside

Current Analyst Ratings Breakdown

Latest ABSI, MRK, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Lower Price TargetEqual Weight$5.90 ➝ $5.60
11/16/2026
Absci Corporation stock logo
ABSI
Absci
Lower Price TargetBuy$15.00 ➝ $14.00
11/16/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Lower Price TargetOverweight$10.00 ➝ $7.00
11/12/2026
Absci Corporation stock logo
ABSI
Absci
Boost Price TargetBuy$11.00 ➝ $15.00
11/12/2026
Absci Corporation stock logo
ABSI
Absci
Reiterated RatingBuy$16.00
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeBuy ➝ Hold$153.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetHold$125.00 ➝ $140.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetNeutral$145.00 ➝ $155.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$165.00 ➝ $175.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetSector Perform$145.00 ➝ $140.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$2.80M506.84N/AN/A$1.27 per share6.47
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.30$11.04 per share12.65$18.23 per share7.66
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M23.89N/AN/A$1.45 per share1.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.79N/AN/AN/A-8,451.31%-61.60%-55.30%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.97143.8715.386.623.64%16.73%5.88%2/2/2027 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$0.90N/AN/AN/A-697.15%-47.85%-36.26%N/A

Latest ABSI, MRK, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1889-$0.19-$0.0011-$0.19$0.66 million$0.30 million
11/2/2026Q3 2026 & Study Update
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.2190-$0.22-$0.0010-$0.22$14.81 million$18.55 million
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.43%+5.75%350.52%14 Years
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ABSI, MRK, and RXRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/17/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.882.46%12/15/202612/15/20261/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
9.64
9.64
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/A
5.01
5.01

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
140172.75 million154.57 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
600622.76 million581.35 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 9.6% on Analyst Downgrade
Recursion Pharmaceuticals Earnings Call Signals Clinical Momentum
2 healthcare stocks to turn $10 into $100 by next year
Recursion to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Absci stock logo

Absci NASDAQ:ABSI

$8.22 +0.64 (+8.38%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$139.69 -3.68 (-2.57%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$2.86 +0.15 (+5.33%)
As of 11:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.